ABSTRACT
In 2012, a proposal sponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology was conceived to unify terminology for human papillomavirus (HPV)-associated squamous lesions throughout the lower anogenital tract, termed Lower Anogenital Squamous Terminology (LAST). [1] [2] [3] [4] For intraepithelial lesions, a two-tiered terminology was recommended, including low-grade lesions and separating them from high-grade lesions. The rationale reflected the biology of transient, productive HPV infections and persistent precancerous lesions. [1] [2] [3] [4] HPV-infected low-grade squamous epithelial lesions, previously termed grade 1 intraepithelial neoplasia, mild Upon completion of this activity you will be able to:
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dysplasia, or, in the appropriate architectural background, condyloma, were now unified under the term lowgrade squamous intraepithelial lesions (LSILs). [1] [2] [3] [4] When and if viral DNA is incorporated into the host cell DNA, viral oncogene overexpression produces a clonal expansion of cells with significant atypia, increasing the risk of squamous carcinoma. [5] [6] [7] These intraepithelial morphologic features, named high-grade squamous intraepithelial lesions (HSILs), include previously named moderate and severe dysplasia (grades 2-3 intraepithelial neoplasia and carcinoma in situ). [1] [2] [3] [4] The LAST project also analyzed the use of biomarkers, particularly the use of p16, and several recommendations were issued. 1, 2, 4 In short, p16 immunostain was recommended when the morphologic differential diagnosis includes a high-grade lesion and a mimicker (eg, immature squamous metaplasia, atrophy, reactive changes). If the pathologist is entertaining a morphologic interpretation of moderate dysplasia (grade 2 intraepithelial neoplasia-using old terminology), p16 immunostain is recommended to help clarify/confirm the diagnosis. Immunostain for p16 is also recommended for use in cases where there is a disagreement in H&E interpretation by different pathologists and a precancer (high-grade) lesion is included in the differential diagnosis. Finally, the indiscriminate use of p16 is discouraged, especially as a tool to differentiate low-grade vs reactive lesions or in unequivocal low-grade dysplasia cases. 1, 2, 4 Our study has two objectives: (1) compare the practice patterns between pathologists in the academic and community settings, including the use of the new nomenclature as well as the use of p16, and (2) analyze the interobserver reproducibility of the new nomenclature.
Regarding the first objective, we speculated that more cases in the academic setting would include the new nomenclature, either outright or in addition to the old nomenclature to gradually introduce it. We were unsure about the use of LAST in the community setting. We were uncertain on the use of p16 in both settings, in part due to many anal biopsy specimens handled by gastrointestinal pathologists in the academic setting who might be less knowledgeable about the recommended indications of p16. We presumed that the new terminology would significantly improve the agreement between pathologists, at least in the academic setting.
Materials and Methods
After institutional review board approval from Cleveland Clinic, a search of the pathology database for cases from the anal region that included all hospitals at the Cleveland Clinic Health System was performed; this included cases from the Cleveland Clinic main campus (academic center with subspecialty), as well as two of the satellite hospitals (community setting). Cases from September 2013 to April 2014 were included in the study (more than 2 years after original publication of LAST). Pathologists at the academic center are subspecialty pathologists; for the most part, pathologists sign out one or two subspecialties, usually with subspecialty fellowship or significant experience in the particular area. In addition, these pathologists are involved in clinical/translational research and teaching the pathology residents and medical students, while pathologists in the community setting acted as generalists at the time of diagnosis of the specimens with generalized sign-outs and no research or teaching duties; none of the community setting pathologists who signed out cases are fellowship trained in gastrointestinal or gynecological pathology.
The search revealed 181 consecutive formalin-fixed anal biopsy specimens. Forty-nine cases were excluded due to tissue material (H&E slides and/or blocks) not available for review. All cases were considered routine biopsy specimens or resections; none were outside consultation cases.
Data on age and sex of the patients, type of hospital where the case originated from (as described above), original diagnosis, if the diagnosis was compatible with LAST, use of p16 immunostain aiding the diagnosis, and interpretation of such immunostain if performed were collected on all cases.
Slides from the available cases were pulled from the files and de-identified; their original diagnoses were tabulated. Cases were then blindly and independently reviewed by all four study pathologists (A.A.R., X.L., D.T.P., and D.A.) (academic setting): three with gastrointestinal expertise (all fellowship trained and 8, 5, and 5 years of experience postfellowship) and one pathologist with gynecological pathology expertise (fellowship trained and 7 years of experience postfellowship). Each pathologist was asked to provide an initial interpretation using classic nomenclature (anal intraepithelial neoplasia [AIN]) as well as into one of four distinct categories, according to LAST-reactive/negative, LSIL (including mild dysplasia/AIN 1 and condyloma), HSIL (including moderate and severe dysplasia/AIN 2-3 and carcinoma in situ), and invasive squamous cell carcinoma (SCC)-based on all available H&E slides and determine if p16 immunostain was necessary for diagnosis. When cases already had p16 immunostain (clone E6H4, prediluted; Ventana Medical Systems, Tucson, AZ) performed at the time of initial diagnosis, the immunostain was provided for interpretation. Appropriate positive control (serous and squamous © American Society for Clinical Pathology AJCP / Original article carcinoma) was included in each case in the same slide and reviewed. Negative controls were run on a separate slide; when not available for review, internal negative control (vessels, colorectal epithelium, and/or stroma) were reviewed and considered appropriate.
In addition, the reviewers were provided with respective p16 immunostains when requested in cases that were not ordered by the original pathologist. p16 immuno stains were performed on the same run, with a separate positive and negative control that were reviewed with appropriate results. Pathologists were asked to grade p16 immunostain results as negative, patchy positive, or diffuse/block positive. A final diagnosis after p16 immunostain interpretation was also provided by each pathologist. A consensus diagnosis was then reached when at least three of the four pathologists provided the same diagnosis/interpretation. If there was a discrepancy, two of the main authors (A.A.R. and D.A.) reviewed the cases and a consensus diagnosis was reached.
Continuous variables were summarized as median and range, with a comparison using the Wilcoxon rank-sum test. Categorical variables were summarized as count and percentage, with a comparison using the Fisher exact test. The interrater agreement was calculated as Fleiss's κ with bootstrap confidence interval. Comparisons with P values less than .05 were considered statistically significant.
Results

Clinicopathologic Findings
In total, 132 anal biopsy specimens from 102 patients were studied (31 female and 71 male patients; mean age, 49 years; median age, 53 years; range, 19-82 years). Fiftysix (42%) of the specimens were seen and diagnosed at an academic center, and the remaining 76 (58%) were diagnosed in the community setting.
Description of Original Histopathologic Diagnosis and Immunostains
Benign squamous mucosa, reactive changes, or no dysplasia were diagnosed in 37 (28%) cases. LAST was appropriately used in 47 (49%) of 95 remaining cases (academic center, 32 [68%]; community setting, 15 [32%] ). This included 26 cases diagnosed as LSIL, 14 as HSIL, and seven as invasive SCC. Cases diagnosed using older terminology included 26 cases diagnosed as condyloma, seven cases diagnosed as mild dysplasia/AIN 1, nine cases diagnosed as moderate dysplasia/AIN 2, four cases diagnosed as severe dysplasia/AIN 3, and two cases diagnosed as squamous carcinoma in situ.
Immunostain for p16 was ordered at the time of original diagnosis in 14 (10.6%) cases, with 13 of those in the academic setting, while in only one occurrence, p16 immunostain was performed in the community setting. Of these, the result was reported as positive (block positive or positive not otherwise specified) in six cases diagnosed as HSIL and/or AIN 2; in the remaining eight cases, p16 immunostain was interpreted as patchy positive, and a diagnosis of LSIL and/or AIN 1 was rendered.
Consensus Review Results and Follow-up
After pathology review and consensus diagnosis, initial diagnoses were reclassified as benign/reactive in 38 cases, LSIL in 54 cases, HSIL in 33 cases, and invasive SCC in seven cases (data are summarized in ❚Table 1❚; images of two cases can be seen in ❚Image 1❚). Discrepancies between the original diagnosis (using other terminologies and LAST) and the consensus diagnosis after review (using only LAST) were found in 23 (17%) cases. Seventeen of these 23 cases had an initial diagnosis other than benign/reactive; LAST criteria were reported in nine (53%) of the cases, while other terminology (intraepithelial neoplasia and/or dysplasia) was reported in the remaining eight (47%) cases.
Six (26.1%) of the discrepant cases were originally diagnosed as benign/reactive and reclassified as dysplastic (five LSILs and one HSIL). Two of the five cases reclassified as LSIL were condylomatous lesions, while the remaining three cases were flat dysplastic lesions. p16 was not originally performed in any of these cases. There was no uniform agreement in these consensus LSIL cases; one reviewer in three cases (same reviewer in all) was concerned for HSIL (AIN 2) and requested an immunostain for p16 that showed patchy expression. Three of these cases were originally diagnosed in an academic center.
A case from the academic setting was reclassified from benign (original) to HSIL (consensus diagnosis) (case 3, Image 1). p16 immunostain was not performed during initial interpretation. All four reviewers were concerned for HSIL (AIN 2) and indicated the need for additional workup. p16 immunostain was performed and interpreted as diffuse/block positive, supporting the HSIL consensus diagnosis. Unfortunately, the patient did not come back for follow-up.
Thirteen (56.5%) of the discrepant cases were originally diagnosed as condyloma/mild dysplasia/AIN 1 or LSIL and reclassified: seven were upgraded to HSIL, and six were downgraded to negative for dysplasia (lack of HPV features and/or basal dysplasia); five of these cases were originally diagnosed in an academic center.
p16 immunostain was requested in all seven cases reclassified as HSIL by one or more reviewers, and it was interpreted as diffusely positive, supporting consensus diagnosis of HSIL. In three of these cases, all four reviewers were concerned for HSIL (AIN 2 and/or AIN 3), and most requested the p16 immunostain (except when the reviewer diagnosis was AIN 3). In one case, three reviewers were concerned for HSIL (AIN 2), but only two requested p16 immunostain. In one case, reviewers were split between LSIL (AIN 1) and HSIL (AIN 2). Those concerned for HSIL requested p16 immunostain. In the remaining two cases, only one reviewer was concerned for HSIL (AIN 2) and requested p16 immunostain; other reviewers diagnosed the cases as LSIL (condyloma or AIN 1). Based on the diffuse p16 immunostain, the consensus diagnosis was HSIL (AIN 2).
Four (17.4%) of the discrepant cases were originally classified as moderate dysplasia/AIN 2, severe dysplasia/ AIN 3, squamous carcinoma in situ, or HSIL and were downgraded to LSIL. Two cases were originally diagnosed in an academic center. In only one case, p16 immunostain was originally ordered and interpreted as positive (case 46, Image 1). A re-review deemed it to have a patchy positive pattern of expression and hence not supportive of HSIL. In this case, three reviewers interpreted the morphology as consistent with LSIL (AIN 1) and did not request p16; the fourth reviewer was concerned for HSIL and ordered p16 immunostain but also interpreted it as positive block/ diffuse and rendered a final classification of HSIL/AIN 2. Agreement review of the case determined that p16 immunostain showed patchy expression and was downgraded to LSIL. The specimen was a skin tag-like resection, and no additional treatment was provided; the patient did not return for follow-up regarding this diagnosis.
In two additional cases (cases 92 and 93), the reviewers were concerned for HSIL and requested the p16 immunostain that showed patchy expression; LSIL was the rendered diagnosis. One patient was followed with anal brushing that was negative 4.5 months later. The other patient had three follow-up biopsies (3, 13, and 18 months), all diagnosed as LSIL.
In the last case (case 52), all reviewers considered the morphology consistent with LSIL; however, two reviewers 
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Discrepancies vs Academic and Community Setting After Consensus
Discrepancies between the original and consensus diagnosis most commonly occurred in the community setting in 14 (20%) cases, while this occurred in nine (16%) instances in the academic setting; however, this was not significantly different (P = NS). The most significant change in diagnosis was seen in 12 cases (underdiagnoses in eight and overdiagnoses in four). In eight cases that finally represented HSIL with diffuse/block p16 expression, diagnoses of LSIL 7 and benign/reactive changes 1 were initially reported. This occurred, we believe, due to the initial pathologist not recognizing the possibility of HSIL and hence not performing p16 immunostain. All or most of the pathologists reviewing the cases were concerned for HSIL in six of these cases and requested p16 immunostain that aided in confirmation ❚Image 1❚ A, Low-power microscopic image of case originally diagnosed as benign that was upgraded to high-grade squamous intraepithelial lesion (HSIL) based on disorganization, atypia, and mitosis involving the entire squamous epithelium (H&E, ×100). B, Immunostain for p16 with diffuse (block) expression supporting the morphologic interpretation of HSIL (×100). C, Low-power microscopic image of anorectal mucosa with classic features of low-grade squamous intraepithelial lesion (LSIL) (H&E, ×40). D, p16 immunostain showing patchy expression but interpreted as diffuse positive by one reviewer and hence interpreted as HSIL by the reviewer; consensus diagnosis was LSIL (×100).
of the H&E impression. However, in two cases, only a single reviewer was concerned for HSIL; p16 immunostain revealed diffuse expression. All reviewers then agreed with the HSIL consensus diagnosis.
Overdiagnoses occurred in four cases diagnosed as HSIL: two originally diagnosed as AIN 3 and two as AIN 2. Only one of these cases (AIN 3) had p16 immunostain initially performed as part of the interpretation. Finally, there was a trend in the community setting to overdiagnose LSIL (condyloma/mild dysplasia/AIN 1) reclassified to negative by consensus in six cases.
Interobserver Agreement Analysis
We compared the interobserver agreement among all pathologists reviewing the cases. Analysis of the overall interobserver agreement among the reviewers was substantial (κ = 0.63) and improved with the use of p16 immunostain in challenging cases (κ = 0.71; P < .001) ❚Table 2❚.
Looking at agreement between pathologists using the classic nomenclature (benign/negative, condyloma, AIN 1-3), full agreement among all four pathologists was seen in 47 (35.6%) of 132 cases: benign, 21; condyloma, 11; AIN 1, two; AIN 2, zero; AIN 3, eight; and invasive SCC, five. In no case did all four pathologists agree on a diagnosis of AIN 2 (33 reviewed HSILs, with nine cases initially diagnosed as AIN 2). Using LAST, full agreement improved to 72 (54.5%) of 132 cases. Agreement of three of the four pathologists using LAST was seen in 93 (70.5%) cases. There were 16 cases with split interpretation among all four reviewers, but since they encompassed condyloma vs AIN 1 and AIN2 vs AIN 3, they were classified in agreement using LAST.
Use of p16 Among Reviewers
In general, the use of p16 immunostain in the original diagnosis varied greatly; reviewers determined that p16 was appropriately ordered for the original diagnosis between three (21%) and eight (57%) of the 14 cases in which p16 was originally ordered. All four reviewers were familiar with LAST and recommendations regarding the use of p16 immunostain. The κ value agreement among all four reviewers regarding interpretation of p16 was substantial (κ = 0.80; 0.70-0.88).
Staining cases for p16 improved diagnostic accuracy for some categories (LSIL and HSIL; Table 2 ). It also improved diagnostic accuracy and interobserver agreement for most reviewers ❚Table 3❚. That being said, it was more clinically relevant in the reviewer who initially had a substantial agreement and, after utilization of p16, had an almost perfect κ.
After reviewing the cases, each reviewer determined when additional p16 was necessary for the final diagnosis. We noted that two of the reviewers (gynecological and gastrointestinal expertise) had a tendency to request p16 less frequently in comparison with the other two reviewers (gastrointestinal expertise) (10 and 19 cases vs 31 and 41 cases each, respectively, P < .001; odds ratio, 0.33; 95% confidence interval [CI], 0.20-0.54). This was not related to years of experience in practice or previous participation in formal studies in squamous dysplasia.
Discussion
Our findings show that the LAST is not yet uniformly used by pathologists in anal/perianal biopsy specimens; less than 50% of the original diagnoses included LAST, even after 2 years of publication, but were more often appropriately applied in the academic setting. Additional distribution of studies detailing LAST and/or follow-up studies could improve the use of this new nomenclature sponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
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The reclassification rate from original to consensus review diagnosis was under 20% and is similar to previously published data in anal lesions. 8, 9 In their study, Pirog et al 8 reviewed 75 anal lesions; most significant discrepancies included one case originally diagnosed as benign that showed AIN 2 on deeper sections cut for immunostains, seven cases of AIN 1 that were reclassified as AIN 2, and one case of AIN 2 that was downgraded to AIN 1, all supported by p16 immunostain. In another study, Bean et al 9 reviewed 77 anal biopsy specimens and resections. After H&E-only review, 13 diagnoses were changed from original to the consensus diagnosis, while in eight additional cases, a consensus diagnosis was not possible. Significant changes included one case upgraded from AIN 1 to AIN 3 and two cases downgraded from AIN 3 to benign. However, one of the latter cases, based on p16 immunostain only, was classified as AIN 3 by two pathologists and AIN 2 by another, while half of the pathologists classified the cases as AIN 2 by combining H&E, p16, and Ki-67 interpretation. 9 This is indicative of the variability of interpreting the morphology alone, immunostains alone, or their combination.
The objective of the study was not necessarily to compare LAST with prior terminology but rather to analyze its use as well as the interobserver agreement among pathologists using the newly proposed terminology that includes rules for p16 utilization. Much has been written regarding interobserver agreement, mostly in HPV-derived cervical squamous dysplasia; κ values for interobserver agreement vary widely. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Crum et al 15 reviewed biopsy-confirmed cervical intraepithelial neoplasia (CIN) grade 2 or 3 from 127 women to determine the degree of interobserver agreement for distinguishing LSIL, HSIL, and nonlesional epithelium. The κ statistic computed between each pair of readers showed κ values that ranged from 0.76 to 0.84, consistent with very good to excellent agreement. Cai et al 17 reviewed 185 slides with preestablished gold-standard CIN diagnoses to characterize agreement of a panel composed of four expert pathologists. In 54.6% of cases, unanimous agreement was reached, mostly in negative (84.5%) cases, while the lowest agreement was in CIN 2 lesions (19.4%). Overall weighted κ was 0.80 (95% CI, 0.78-0.82), again lowest in CIN 2 lesions (κ = 0.38; 95% CI, 0.33-0.44). These data contrast with data from interobserver agreement of community pathologists on cervical biopsy specimens using H&E only that reached κ = 0.566. 20 Horn et al 18 reported similar κ values by analyzing interobserver agreement in 247 cervical biopsy specimens (κ = 0.49) and 249 cervical resections (κ = 0.63). Older studies have reported even lower agreement rates (κ = 0.23 and κ = 0.36). 10, 12 Interobserver agreement specifically in anal lesions also has been reported. 8, 9, [22] [23] [24] In a recent study, Bean et al 9 reported fair agreement among four pathologists with varied experience using H&E diagnosis alone in 77 anal biopsy specimens and resections (κ = 0.38). p16 diagnostic evaluation alone demonstrated the highest agreement (κ = 0.57), while combined H&E/p16/Ki-67 showed moderate agreement (κ = 0.44). Previously, Lytwyn et al 24 reported overall agreement (weighted κ = 0.59) for biopsy specimens, while Carter et al 22 reported only moderate agreement among the pathologists, with unweighted κ scores ranging from 0.09 to 0.48 and weighted κ scores of 0.17 to 0.60.
When Bean et al 9 combined AIN 2 and 3, κ values increased; H&E-only κ values were 0.68, similar to p16 only; while the H&E, p16, and Ki-67 κ value was 0.5, supporting agreement on a two-tiered system of HPV-related squamous lesions conceived to align terminology and due to low reproducibility on grade 2 intraepithelial lesions (-IN 2) lesions. 1, 2, 4 In our study, analysis of the overall interobserver agreement among the reviewers was substantial (κ = 0.63) and improved with the use of p16 immunostain in challenging cases (κ = 0.71), better than previously reported in AIN lesions and comparable to that reported in CIN lesions.
One of the goals was to also analyze the use and interpretation of p16 among the academic and community practice settings. The use of p16 immunostain in the community setting, according to LAST recommendations, occurred in a single case ultimately diagnosed as LSIL (condyloma). LAST working group 4 recommendation 2 suggests, "If the pathologist is entertaining an H&E morphologic interpretation of -IN 2 (under the old terminology), which is a biologically equivocal lesion falling between the morphologic changes of HPV infection (low-grade lesion) and precancer, p16 immunostain is recommended to help clarify the diagnosis. Strong and diffuse block-positive p16 results support a categorization of precancer. Negative or non-block-positive staining strongly favors an interpretation of low-grade disease or a non-HPV-associated pathology." In our study, p16 immunostain was infrequently employed to support a diagnosis of AIN 2 or when the differential diagnosis included AIN 2 and a mimicker, even in the academic environment; only in three of 13 cases with original AIN 2 diagnosis was p16 immunostain used to aid in the interpretation (all p16 immunostains were interpreted as diffuse/block positive © American Society for Clinical Pathology Roma et al / Terminology for AnAl SquAmouS leSionS in these cases). The most significant reclassified diagnoses included eight cases upgraded to HSIL from benign or LSIL after p16 immunostain requested by reviewers. Four cases were downgraded from HSIL to LSIL; p16 immunostain was not used to aid in the original diagnosis and, when performed, supported the reclassified diagnoses.
p16 immunostain was ordered in approximately 10% of the cases for the original diagnosis. This is in keeping with reported values from prior studies in cervical squamous dysplasia. 25 While the use of p16 immunostains in the academic setting was more frequent, it could lead to overuse; the rate of p16 utilization doubled in two reviewers. It is also interesting that community pathologists ordered it so infrequently, and we can only speculate regarding the reasons, including the lack of knowledge about the immunostain applicability to the additional delay introduced to turnaround time if p16 is performed. While the scenarios suitable for p16 use are straightforward, in clinical practice, there seems to be room for interpretation, leading to some unnecessary studies. The problem is that if p16 immunostain is diffusely/block positive, then the final diagnosis would be HSIL. While it might be the correct diagnosis, it could induce a tendency to establish p16 immunostain as the gold standard, independently of the H&E interpretation; this has been already suggested by Dijkstra et al 26 in cervical dysplasia. Most studies, however, report on "outlier cases" where p16 and the morphology are discrepant. There are four possibilities of such an occurrence, as reviewed by Walts et al. 27 These include incorrect diagnoses performed with H&E (ie, p16 is the gold standard), p16 expression can determine cases that will progress before being morphologically identified (ie, integration of high-risk HPV DNA into the host genome may have occurred without eliciting the usual cytopathologic effects recognized as dysplasia), p16 overexpression could be associated with a low-risk HPV subtype (hence, overdiagnosis), and/ or some cases of squamous dysplasia may not be HPV related and hence lack p16 expression. 27 Attempts to identify better or additional markers, including Ki-67, ProEx C, and, more recently pan-HPVE 4, have reported variable success. [28] [29] [30] [31] [32] [33] [34] Knowing when to order p16 immunostain is important, but that is not all; it is probably even more important to correctly interpret the result. Strong and diffuse block-positive p16 immunostain supports categorization of precancerous disease (ie, classification of the lesion as HSIL). 1, 2, 4 In HSIL, positive p16 is strong and diffuse in the dysplastic areas; this is defined as continuous strong nuclear or nuclear plus cytoplasmic staining of the basal cell layer with extension upward involving at least onethird of the epithelial thickness; full-thickness staining or extension into the upper third or upper half is specifically not required to interpret as positive. 1, 2, 4 Focal or patchy nuclear staining is nonspecific and can be seen with reactive squamous metaplasia and low-grade disease as well as all other staining patterns (cytoplasmic only, scattered or single cells, defined as negative). 1, 2, 4 One of the reviewers in our study requested p16 in cases classified as LSIL by consensus and diagnosed as HSIL due to positive p16; however, the pattern of expression was patchy according to these guidelines. Focal staining was interpreted as diffuse due to multiple foci of clustered positive cells but not representing block/diffuse staining. A similar situation occurred in two cases by another reviewer.
It is also important to note that the concept of continuous block staining requires an adequate size and orientation of the tissue; small fragments, tangential cuts, or free-floating single cells may lead to variable interpretations. 1, 2, 4 In our clinical practice, we noticed that some pathologists tend to order p16 immunostain when a highgrade lesion is in the differential diagnosis, but especially in very small fragments of squamous epithelium that morphologically are insufficient for a diagnosis of HSIL. Other pathologists of the team would not have requested p16; it is then difficult to interpret positive staining in a fragment of 10 to 12 cells. Based on our clinical experience, we advise following the LAST recommendations and performing p16 when required but not in most cases, so that HSIL is not missed.
The limitations of our study include its retrospective nature, and while we attempted to analyze a consecutive series of cases, some could not be included due to lack of tissue in the block or material not available for review. In addition, all reviewers were from an academic center, and both reviewers with fewer p16 immunostain requests had a closer and longer interaction reviewing cases in clinical practice outside this study and might have developed a similar threshold in interpreting and working up squamous lesions. In summary, LAST recommendations are not yet uniformly used by pathologists in anal/perianal biopsy specimens, and additional training in this area is needed. This two-tier system has a good interobserver agreement in anal lesions and is further improved with the use of p16 in appropriate cases. It is also recommended that pathologists do not use p16 indiscriminately and/or in very small fragments that can jeopardize its role as an aid in the diagnosis of HSIL.
